Every Form 4 that Grace Therapeutics, Inc. (GRCE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GRCE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRCE filings page.
Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P. The fund bought 9,393 shares on September 8, 2026 at a weighted average price of $2.0972 per share and 5,836 shares on September 9, 2026 at a weighted average price of $2.0899 per share in open-market or private transactions. The prices reflect ranges of $2.095–$2.10 and $2.085–$2.09, respectively, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest; no Rule 10b5-1 trading plan is reported.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli purchased 100,000 shares of common stock on September 9, 2026 in an open-market or private transaction at $2.14 per share. Following this purchase, he directly holds 121,357 shares of Grace Therapeutics common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Grace Therapeutics, Inc. (GRCE) reported that officer Kumar Amresh, VP Program Management, received a grant of stock options for 35,760 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27, with post-grant holdings of 35,760 options.
According to the award terms, the options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting over the following 11 quarters, subject to Mr. Amresh’s continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Medical Officer Macdonald R. Loch received a grant of 54,690 stock options on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27. They vest quarterly over three years, with 1/12 vesting immediately and the remaining 11/12 in equal quarterly installments, subject to continuous service.
Grace Therapeutics, Inc. (GRCE) reported that Chief Executive Officer and director Prashant Kohli received a grant of 267,160 stock options on 2026-08-28. The options have an exercise price of $2.12 per share, expire on 2036-08-27, and relate to 267,160 shares of common stock. According to the vesting terms, 1/12 of the options vested immediately on the grant date and the remaining 11/12 vest in substantially equal quarterly installments over the following 11 quarters, subject to his continuous service.
Grace Therapeutics, Inc. (GRCE) reported that its Principal Financial Officer, Robert J. DelAversano, received a grant of stock options covering 33,660 shares of common stock on 2026-08-28. The options have an exercise price of $2.12 per share and expire on 2036-08-27.
These options vest quarterly in substantially equal installments over three years, with 1/12 vesting immediately on the grant date and the remaining 11/12 vesting equally over the following 11 quarters, subject to his continuous service. Following this award, he holds 33,660 derivative securities of this type directly.
Grace Therapeutics, Inc. (GRCE) had a Form 4 filed for Opaleye Management Inc., a more-than-ten-percent holder, reporting an open-market purchase of 11,608 shares of common stock on August 14, 2026 at a weighted average price of $2.0853 per share. The shares are held indirectly by Opaleye, L.P., with Opaleye Management Inc. potentially deemed a beneficial owner through its role as investment manager but disclaiming beneficial ownership except to the extent of its pecuniary interest. Following this transaction, 2,760,000 shares are reported as held indirectly by Opaleye, L.P.
Grace Therapeutics, Inc. director Vimal Kavuru reported a grant of stock options on January 8, 2026. He received a stock option to buy 10,000 shares of Grace Therapeutics common stock at an exercise price of $3.8 per share, held in direct ownership. Following this grant, he beneficially owns options for 10,000 shares.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, provided he continues to serve the company through each vesting date.
Grace Therapeutics, Inc. director Kottayil George reported a grant of a stock option covering 10,000 shares of common stock of Grace Therapeutics. The option, with an exercise price of $3.8 per share, was awarded on January 8, 2026 and is held directly.
According to the vesting terms, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to George’s continued service on each vesting date.
Grace Therapeutics director Edward Neugeboren received a grant of stock options on January 8, 2026. The award is a stock option (right to buy) covering 10,000 shares of common stock at an exercise price of $3.8 per share, with no cost to receive the option itself.
According to the disclosure, 25% of the option vests on the grant date, and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, as long as Neugeboren continues in service. After this grant, he holds 10,000 derivative securities directly.
Grace Therapeutics director reports stock option grant. Director Brian A. Davis reported receiving a stock option to buy 10,000 shares of Grace Therapeutics, Inc. common stock on January 8, 2026 at an exercise price of $3.8 per share. The filing shows that 25% of the option vests on the grant date, with the remaining 75% vesting in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to his continuous service. Following this grant, he beneficially owned 10,000 derivative securities directly.